Colorectal Cancer Clinical Trial
Official title:
PillCam Colon Capsule and CT-colonography in the Evaluation of Patients With Incomplete Conventional Colonoscopy
| Verified date | November 2015 |
| Source | Catholic University of the Sacred Heart |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Italy: Ethics Committee |
| Study type | Interventional |
Colorectal cancer (CRC) is the second most common cause of cancer-related death in the
Western world, with 500000 deaths per year worldwide. Colonoscopy is accepted as a primary
CRC screening tool in many countries. As a preventative procedure, its main purpose is to
enable the early diagnosis of CRC at a curable stage and to identify and remove
pre-malignant adenomas. Cecal intubation is associated with an increased detection rate of
advanced neoplasia, as 33-50% of advanced neoplasia is located in the proximal colon.
Complete colonic evaluation is therefore a well-recognized measure of colonoscopy quality
control. Cecal intubation rates of ≥ 90% of all colonoscopies in routine clinical practice
and ≥ 95% in screening colonoscopies are recommended. Unfortunately, the cecal intubation
rate in daily clinical practice is often lower than the target of ≥ 90%, with reported
percentages varying from 76.9% to 98.4%. This means that after an incomplete colonoscopy,
malignant and pre-malignant lesions may be missed if further investigation is not pursued.
Several explanatory factors for incomplete colonoscopy have been described. After an
incomplete conventional colonoscopy, patients are required to undergo another test to
complete the visualization of the colon. Options for incomplete examinations because of
anatomic reasons include both radiologic and endoscopic means.
CT Colonography (CTC ) permits to visualise the whole colon, is minimally invasive, does not
require sedation and is well accepted by the patient.
The PillCam Colon Capsule Endoscopy (Given® Diagnostic System)offers an alternative approach
for endoscopic visualization of the colon in patients with an incomplete conventional
colonoscopy. Advantages of the PillCam Colon Capsule Endoscopy (PCCE) include the
elimination of the need for sedation, the minimally invasive, painless nature of the exam,
no need of X-rays and the ability to pursue normal daily activities immediately following
the procedure. This is a study that is designed to evaluate the performance of the PCCE in
the evaluation of patients with an incomplete colonoscopy, compared to the CT-colonography.
PCCE and CT-colonography procedures will be compared in regards to completeness of the
procedure and detection of lesions in the colon that would have been missed by the
incomplete conventional colonoscopy.
| Status | Completed |
| Enrollment | 100 |
| Est. completion date | December 2013 |
| Est. primary completion date | December 2013 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | Both |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Subject is between the ages of 18-75 years. - Subject is referred for colonoscopy as clinically indicated for any reason. This may include, but not limited to, the investigation of any of the following conditions: rectal bleeding, melena, positive stool testing for occult blood, recent change of bowel habits, screening for colorectal cancer, colonic findings on an imaging study - Subject in which conventional colonoscopy was incomplete Exclusion Criteria: - Subject has dysphagia or any swallowing disorder - Subject has Congestive heart failure - Subject has high degree of renal insufficiency - Subject has had prior abdominal surgery of the gastrointestinal tract other than uncomplicated procedures that would be unlikely to lead to bowel obstruction based on the clinical judgment of the investigator - Subject has a cardiac pacemaker or other implanted electromedical device. - Subject has any allergy or other known contraindication to the medications used in the study - Subject is expected to undergo MRI examination within 7 days after ingestion of the capsule. - Subject with any condition believed to have an increased risk for capsule retention such as Crohn's disease, intestinal tumors, radiation enteritis, or NSAID enteropathy, - Subject has any condition, which precludes compliance with study and/or device instructions. - Women who are either pregnant or nursing at the time of screening, who intend to be during the study period, or are of child bearing potential and do not practice medically acceptable methods of contraception - Subject suffers from life threatening conditions - Subject currently participating in another clinical study - Iodine contrast allergy - Hyperthyroidism - Inflammatory bowel disease |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Country | Name | City | State |
|---|---|---|---|
| Italy | Catholic University of Sacred Hearth | Rome |
| Lead Sponsor | Collaborator |
|---|---|
| Catholic University of the Sacred Heart |
Italy,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | To evaluate the completeness of colonic exploration in patients with a previous incomplete conventional colonoscopy due to technical failure (not due to inadequate cleansing level). | 12 months | No | |
| Secondary | To evaluate the difference in terms of accuracy and completeness between PCCE and CT-colonography | 12 months | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
| Completed |
NCT00098787 -
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
|
Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT05425940 -
Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer
|
Phase 3 | |
| Suspended |
NCT04595604 -
Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery.
|
N/A | |
| Completed |
NCT03414125 -
Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening
|
N/A | |
| Completed |
NCT02963831 -
A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Terminated |
NCT01847599 -
Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib
|
N/A | |
| Completed |
NCT05799976 -
Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure
|
N/A | |
| Recruiting |
NCT03874026 -
Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT03181334 -
The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation
|
N/A | |
| Completed |
NCT03167125 -
Participatory Research to Advance Colon Cancer Prevention
|
N/A | |
| Recruiting |
NCT04258137 -
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
|
N/A | |
| Recruiting |
NCT05568420 -
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
|
||
| Recruiting |
NCT02972541 -
Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer
|
N/A | |
| Completed |
NCT02876224 -
Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors
|
Phase 1 | |
| Completed |
NCT01943500 -
Collection of Blood Specimens for Circulating Tumor Cell Analysis
|
N/A |